Bloomberg
AbbVie Officially Scraps Shire Tax Inversion Deal
Oct. 21 -- Bloomberg's Scarlet Fu reports on the top company news of the day on ""Bloomberg Surveillance.
Bloomberg
What Makes Allergan an Attractive Target for Actavis?
Nov. 12 -- Reports link Actavis to talks with Allergan on an acquisition that could be worth more than $60 billion dollars. Bloomberg's Jeff McCracken breaks down the potential deal, how it got to this point and the players involved on...
Bloomberg
Glaxo Accelerates Ebola Vaccine
Oct. 20 -- In ""Company News,"" Bloomberg's Jonathan Ferro reports on the top business stories of the day. He speaks on Bloomberg Television's ""On The Move."" (Source: Bloomberg)
Bloomberg
The Top Three Stocks to Watch in Asia Today
Jan. 7 -- In todays Stock Exchange, Bloomberg's John Dawson, Yvonne Man and Shery Ahn discuss todays top three stocks to watch in Asia on First Up. (Source: Bloomberg)
Bloomberg
Bill Ackman: Herbalife Implosion Coming in 2015
Dec. 17 -- Bill Ackman, chief executive officer at Pershing Square, discusses when he sees the end game for Herbalife and new internal video hes obtained to back up his allegations that Herbalife is a pyramid scheme two years after his...
Bloomberg
Why Express Scripts Chose AbbVie Over Gilead
Dec. 22 -- Bloomberg's Drew Armstrong discusses pharmaceuticals and the health care industry with Mia Saini on Bottom Line. (Source: Bloomberg)
Bloomberg
Bring Health to Your Portfolio With Pharma ETFs
July 1 -- Bloomberg Intelligence's Eric Balchunas examines investment opportunities in pharma ETFs. He speaks on "Bloomberg Markets."
Bloomberg
Valeant CEO Makes His Case Right to Analysts
March 2 -- Valeant Chief Executive Officer Mike Pearson spoke one-on-one with some sell-side analysts to explain his need for time to understand the company after being away from it for two months. Bloomberg's Drew Armstrong reports on...
Bloomberg
Bill Ackman Takes Bigger Role at Valeant
Mar 22 -- Bloomberg’s Drew Armstrong reports on what’s next for Valeant on "Bloomberg Markets.†(Source: Bloomberg)
Bloomberg
Why J&J Is Buying Actelion for $30 Billion
Jan.26 -- Johnson & Johnson's $30 billion acquisition of Actelion Ltd. specifies that the deal be paid in U.S. dollars, despite the fact that Actelion shares are priced in Swiss francs. Bloomberg Gadfly columnist Max Nisen breaks down...
Bloomberg
BeiGene's CEO on HK Debut, China Growth Strategy, Regulation
Aug.08 -- John Oyler, founder and chief executive officer at BeiGene, discusses why he chose Hong Kong for the company's second listing, his growth strategy for China, the regulatory environment in China, partnerships and how their...
Bloomberg
Ascletis Pharma Debuts in Hong Kong
Jul.31 -- Ascletis Pharma makes its debut in Hong Kong. Bloomberg's Crystal Tse and Sophie Kamaruddin report on "Bloomberg Markets: Asia."
Bloomberg
Gilead to Raise Stake in Galapagos
Jul.15 -- Gilead is paying $5.1B to raise its stake in the Belgian biotech firm Galapagos to gain access of a portfolio of compounds including 6 already in clinical trial. Bloomberg’s Sarah Syed reports on “Bloomberg Markets: European...
Bloomberg
Kodak Will Help Make Medicines to Fight Covid, Says Trump
Jul.28 -- Eastman Kodak Co. shares more than tripled Tuesday on plans to secure a $765 million government loan to help produce ingredients used in key generic medicines to fight the coronavirus. The money could provide a lifeline to the...
Bloomberg
Roche Will Be `Thoughtful' on Regeneron Pricing, CEO Says
Oct.15 -- Roche Holding AG Chief Executive Officer Severin Schwan discusses the antibody cocktail that the Swiss drugmaker is developing with Regeneron Pharmaceuticals Inc. to treat Covid-19. He speaks from Basel, Switzerland, on...
Bloomberg
India's PharmEasy Aims to Make Drugs More Accessible: Co-Founder
Jul.09 -- Siddharth Shah, co-founder of PharmEasy, India’s largest online pharmacy, discusses the company's strategy. PharmEasy is owened by API Holdings, the country's largest and fully-integrated digital healthcare company. API has...
Bloomberg
Cumberland Advisors Is 'Overweight' Health-Care: CIO
Jul.20 -- David Kotok, chairman and chief investment officer of Cumberland Advisors, discusses the opportunities he sees in the markets amid the Covid pandemic. He speaks with Haidi Stroud-Watts and Shery Ahn on "Bloomberg Daybreak: Asia."
Bloomberg
J&J Plans to Split Into Drug, Consumer Companies
Johnson & Johnson announced plans to break itself up into two public companies, splitting drugs and medical devices from consumer products in 18 to 24 months. Bloomberg Intelligence's Sam Fazeli has the details.
Bloomberg
J&J Booster Vaccine to Be Available Soon, CFO Says
Johnson & Johnson CFO and Executive Vice President Joe Wolk discusses the company's earnings, the strength of its pharma business and the state of Covid-19 booster shots. He speaks with Bloomberg's Alix Steel and Guy Johnson on...
Bloomberg
Europe Stocks to Watch: Hospitality, Supermarkets
Bloomberg's Joe Easton has a rundown of the stocks to watch in Europe today including JD Wetherspoon Plc, J Sainsbury Plc, and AstraZeneca Plc.
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features,...
Bloomberg
What's Causing the M&A Frenzy in Pharmaceuticals?
Oct. 21 -- Actavis is among the bidders for Omega Pharma, people with knowledge of the matter said, as the U.S. drugmaker continues hunting for acquisitions. Bloomberg's Drew Armstrong examines what's causing the recent consolidation in...